Earli
Jeffrey Kuan serves as the Associate Director of Process Development at Earli Inc. since October 2024, following a significant tenure at Gritstone bio where Kuan held multiple roles including Senior Manager of Drug Product Development & Process Engineering. Kuan's expertise encompasses leading lipid nanoparticle (LNP) encapsulation projects for mRNA drugs, managing teams, and driving late-stage development activities for immuno-oncology products. Additionally, prior experience includes roles at Adverum Biotechnologies, Boehringer Ingelheim, and Genentech, with a strong background in process optimization, scale-up activities, and regulatory compliance. Kuan holds a Bachelor of Science degree in Chemical Engineering from the University of California, Berkeley.
This person is not in any teams
Earli
1 followers
Earli has an ambitious mission: to force cancer reveal its location at its earliest stages, which makes it quickly treatable. In other words, they aim to make cancer a benign experience. Their science is based on a new method of detecting, localizing and then treating cancer called "Synthetic Biopsies," originally developed by the late Dr. Sam Gambhir at Stanford.